|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Xilio Therapeutics, Inc. (XLO) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
26,671,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve clinical responses to improve the lives of patients with cancer. Co. is developing a number of tumor-selective, agents through various stages of development. Co.'s product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody and XTX202, an interleukin 2 therapy. Co. is also developing its tumor-selective IL-12 product candidate, XTX301 and is focusing on preclinical studies for its tumor-selective IL-15 product candidate, XTX401. Co. has worldwide development and commercialization rights to all of its product candidates.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
485,250 |
485,250 |
485,250 |
485,250 |
Total Buy Value |
$368,790 |
$368,790 |
$368,790 |
$368,790 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
1,000 |
5,235 |
5,235 |
5,235 |
Total Sell Value |
$640 |
$4,240 |
$4,240 |
$4,240 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
2 |
6 |
6 |
6 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gilead Sciences Inc |
10% Owner |
|
2024-04-02 |
4 |
B |
$0.76 |
$368,790 |
D/D |
485,250 |
7,345,473 |
2.45 |
- |
|
Gilead Sciences Inc |
10% Owner |
|
2024-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,860,223 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2024-02-08 |
4 |
S |
$0.64 |
$171 |
I/I |
(267) |
734,546 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2024-02-08 |
4 |
S |
$0.64 |
$469 |
D/D |
(733) |
2,019,563 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2024-01-12 |
4 |
S |
$0.83 |
$465 |
I/I |
(560) |
734,813 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2024-01-12 |
4 |
S |
$0.83 |
$1,278 |
D/D |
(1,540) |
2,020,296 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2024-01-11 |
4 |
S |
$0.87 |
$495 |
I/I |
(569) |
735,373 |
|
- |
|
Atlas Venture Associates Opportunity I, Llc |
10% Owner |
|
2024-01-11 |
4 |
S |
$0.87 |
$1,362 |
D/D |
(1,566) |
2,021,836 |
|
- |
|
English Edward C |
Principal Accounting Officer |
|
2022-11-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,002 |
|
- |
|
Bcip Life Sciences Associates, Lp |
10% Owner |
|
2021-12-10 |
4 |
B |
$9.56 |
$241,202 |
I/I |
25,000 |
2,805,413 |
1.5 |
- |
|
Bcip Life Sciences Associates, Lp |
10% Owner |
|
2021-12-09 |
4 |
B |
$9.84 |
$39,485 |
I/I |
4,011 |
2,780,413 |
1.5 |
- |
|
Bcip Life Sciences Associates, Lp |
10% Owner |
|
2021-12-08 |
4 |
B |
$9.62 |
$129,474 |
I/I |
13,458 |
2,776,402 |
1.5 |
- |
|
Bcip Life Sciences Associates, Lp |
10% Owner |
|
2021-10-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,762,944 |
|
- |
|
Sv7 (imf) Gp Llp |
10% Owner |
|
2021-10-26 |
4/A |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
1,613,632 |
1.5 |
- |
|
Sv7 (imf) Gp Llp |
10% Owner |
|
2021-10-26 |
4/A |
B |
$16.00 |
$5,000,000 |
D/D |
312,500 |
1,613,632 |
2.45 |
- |
|
Fmr Corp |
See Remark 1 |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
1,881,355 |
4,465 |
|
- |
|
Fil Ltd |
See Remark 1 |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
218,705 |
218,705 |
|
- |
|
Sv7 (imf) Gp Llp |
10% Owner |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
1,301,132 |
1,301,132 |
|
- |
|
Sv7 (imf) Gp Llp |
10% Owner |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,301,132 |
1,301,132 |
|
- |
|
Deerfield Mgmt V, L.p. |
Possible Member of 10% Group |
|
2021-10-26 |
4 |
B |
$16.00 |
$12,400,000 |
I/I |
775,000 |
1,143,972 |
1.5 |
- |
|
Deerfield Mgmt V, L.p. |
Possible Member of 10% Group |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
1,512,944 |
756,472 |
|
- |
|
Takeda Ventures, Inc. |
10% Owner |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
1,475,121 |
1,475,121 |
|
- |
|
Rivervest Venture Fund Iv, L.p. |
10% Owner |
|
2021-10-26 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
1,441,444 |
1.5 |
- |
|
Rivervest Venture Fund Iv, L.p. |
10% Owner |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
1,191,444 |
1,191,444 |
|
- |
|
Merck Kgaa |
10% Owner |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
680,825 |
680,825 |
|
- |
|
41 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|